Veeva Basics Adoption Tops 175 Emerging Biotech Firms
Veeva says more than 175 emerging biotechs use its pre-configured software, while the announcement did not quantify revenue from the offering.
Key takeaways
- More than 175 emerging biotech companies use Veeva Basics.
- Veeva said customers can implement the pre-configured applications in weeks.
More than 175 emerging biotechnology companies are using Veeva Basics to build technology infrastructure and streamline drug development, Veeva Systems announced.
The offering runs on Veeva’s Vault Platform and provides pre-configured applications for clinical, regulatory, quality, medical and commercial work. Veeva said customers can implement the applications in weeks and expand them as their businesses grow.
The announcement did not quantify expected revenue from Veeva Basics. Wider adoption could create opportunities to expand customer relationships as biotech firms grow, but the financial benefit will depend on retention and customers’ ability to scale, according to the source.
This article was produced with the help of AI technology. Source: Yahoo Finance
